Drug-drug interaction study (1) of Tofogliflozin

Drug-drug interaction study (1) of Tofogliflozin (CSG452) in healthy adult male volunteers

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221599

Enrollment

Registered

2011-09-29

Start date

2011-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabets

Interventions

investigational material(s) Generic name etc : Tofogliflozin INN of investigational material : Tofogliflozin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investiga

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -healthy volunteers -Body mass index (BMI) >=18.5 kg/m2 and = 90 mL/min/1.73 m2 -Has not smoked for at least a year before screening and will not smoke during the study period Etc.

Exclusion criteria

Exclusion criteria: Has been administered any of the medicines, foods and drinks that can affect the pharmacokinetics of Tofogliflozin or concomitant drugs to be tested for drug-drug interactions within two weeks before administration in Period I Etc.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics, Safety Evaluate the pharmacokinetics and safety of Tofogliflozin and concomitant drugs to be tested for drug-drug interactions when administered each other alone or in combination with both.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026